[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-442941-105":59,"doc-detail-442941-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","real-world-cardiac-events-and-outcomes-in-cbtki-treated-chronic-lymphocytic-leukemia-patients","Real-world cardiac events and outcomes in cBTKi-treated chronic lymphocytic leukemia patients","","Aim: evaluate the real-world incidence of cardiovascular adverse events (CVAE) and clinical outcomes in chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) patients treated with covalent Bruton’s Tyrosine Kinase inhibitors (cBTKis). Methods: claims-based identification of patients initiating cBTKi therapy from 1 Jan 2020 to 1 Jan 2023; demographics, line of therapy (1L vs 2L+), incident CVAEs, and outcomes assessed. Results: 2,163 patients; CVAEs linked to higher next-treatment switching plus death and worse overall survival; acalabrutinib showed lower incidence than ibrutinib for key CVAEs; 12-month CVAE-free probabilities reported. Conclusions: substantial cardiovascular burden persists despite 2nd-generation cBTKi improvements.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/real-world-cardiac-events-and-outcomes-in-cbtki-treated-chronic-lymphocytic-leukemia-patients/442941/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/real-world-cardiac-events-and-outcomes-in-cbtki-treated-chronic-lymphocytic-leukemia-patients/442941.png","ImageObject",300,407,{"name":92,"@type":93},"acoobca","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-05","2026-09-29",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",13,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What is the document’s main aim regarding cBTKi and CLL/SLL?","Question",{"text":113,"@type":114},"It evaluates the real-world incidence of cardiovascular adverse events (CVAE) and the associated clinical outcomes in CLL/SLL patients treated with cBTKis.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How were patients selected and what data were analyzed?",{"text":118,"@type":114},"Patients initiating cBTKi from 1 January 2020 to 1 January 2023 were identified using claims data, and demographics, therapy line (1L vs 2L+), incident CVAEs, and outcomes were assessed.",{"name":120,"@type":111,"acceptedAnswer":121},"What relationship did the study find between CVAEs and patient outcomes?",{"text":122,"@type":114},"Patients experiencing CVAEs had higher switching to next treatment plus death and worse overall survival than those without CVAEs.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},442941,1790888801,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":41,"preview_page_count":4},3985747870733,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","FUTURE ONCOLOGY  \n2026, VOL. 22, NO. 1, 71–82  \n[https://doi.org/10.1080/14796694.2025.2600913](https://doi.org/10.1080/14796694.2025.2600913)  \n| RESEARCH ARTICLE   \u003Cbr>Real-world cardiac events and outcomes in cBTKi-treated chronic lymphocytic leukemia patients\u003Cbr>David Dinglia, Enrico De Nigrisb, Siyang Lengc, Mohammed Z. H. Farooquic, Halit O. Yapicid, Ian Weimerd, Weiqi Jiaod, Hayden Hyattd, Xuan Zhangd, Kunal Lodayad and Mavis Obeng-Kusic\u003Cbr>aDivision of Hematology, Mayo Clinic, Rochester, MN, USA; bOutcomes Research, MSD (UK) Limited, London, UK; cMerck & Co., Inc., Rahway, NJ, USA; dBoston Strategic Partners, Inc., Boston, MA, USA |  |  |\n| --- | --- | --- |\n| ABSTRACT\u003Cbr>Aim: To evaluate the real-world incidence of cardiovascular adverse events (CVAE) and clinical outcomes among patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) treated with covalent Bruton’s Tyrosine Kinase inhibitors (cBTKis) .\u003Cbr>Methods: Patients initiating cBTKi treatment from 1 January 2020 to 1 January 2023 were identified using claims data. Demographics, first-line (1L) and second-line or later (2L+) therapy, incident CVAEs, and clinical outcomes were assessed.\u003Cbr>Results: In total, 2,163 patients (81.4% in 1L and 18.6% in 2L+) were identified with a mean age of 73.8 􀀆 9.2 years and 40.6% female. The most common incident CVAEs were hypertension (23.4%), atrial fibrillation (10.2%), ventricular arrhythmias (10.1%), heart failure (8.5%), and atrial flutter (4.2%) . Those with CVAEs experienced higher switching to next treatment + death and worse overall survival than those without CVAEs. Incidence rates were ~2–3 fold lower with acalabrutinib than ibrutinib for hypertension, atrial fibrillation, and atrial flutter. Kaplan-Meier estimates for the likelihood of not experiencing a CVAE were 83%(acalabrutinib) and 72%(ibrutinib) at 12-months.\u003Cbr>Conclusions: Despite improvements in 2nd-generation cBTKi cardiotoxicity, patients with CLL/SLL receiving cBTKis have a considerable cardiovascular disease burden. These findings highlight the unmet need for CLL/SLL treatment options with improved efficacy and safety profiles. |  | ARTICLE HISTORY\u003Cbr>Received 16 June 2025 Accepted 4 December 2025\u003Cbr>KEYWORDS\u003Cbr>Acalabrutinib; ibrutinib; zanubrutinib; BTK inhibitor; real-world outcomes; cardiac complications; cardiac events; chronic lymphocytic leukemia |\n| 1. Introduction\u003Cbr>Chronic lymphocytic leukemia and small lymphocytic lymphoma (CLL/SLL) are lymphoid neoplasms characterized by the clonal proliferation of mature small CD5+ B cells in the blood, bone marrow, lymphoid tissues, and extranodal sites [1]. CLL/SLL are different manifestations of the same disease, with abnormal lymphocytes being found primarily in the blood, lymph nodes, and bone marrow for CLL and in the lymph nodes for SLL [2]. CLLis the most common form and is the second most common typeof leukemia in the United States, with an estimated 20,700 new cases in 2024 [3].\u003Cbr>Treatment of CLL/SLL in the United States was revolutionized in 2014 with the approval of ibrutinib, a first generation covalent Bruton’s tyrosine kinase inhibitor (cBTKi). Specifically, cBTKis inhibit B cell antigen receptor signaling, which plays a key role in abnormal B cell survival, proliferation, and differentiation [4,5]. Findings from the RESONATE and RESONATE-2 studies revealed considerable increases in progression-free survival with ibrutinibin treatment naïve patients and those receiving second line or later lines (2L+) of therapy, respectively, with 59% of patients experiencing progression free survival at 7-years compared to 9% in chlorambucil treated patients [6,7]. Subsequent clinical trials have further shown the efficacy of second generation | cBTKis (e.g., acalabrutinib and zanubrutinib) for the treatment of CLL/SLL [8–10]. The profound clinical utility of cBTKis led to their use as standard of care in both treatment-naïve andrelapsed/refractory patients with CLL/SLL [11].\u003Cbr","cbCaiuVowHh3qQ7F","https://ap.wps.com/l/cbCaiuVowHh3qQ7F","pdf",4464070,12,"English","# Abstract\n## Aim\n## Methods\n## Results\n## Conclusions\n# 1. Introduction","[{\"question\":\"What is the document’s main aim regarding cBTKi and CLL/SLL?\",\"answer\":\"It evaluates the real-world incidence of cardiovascular adverse events (CVAE) and the associated clinical outcomes in CLL/SLL patients treated with cBTKis.\"},{\"question\":\"How were patients selected and what data were analyzed?\",\"answer\":\"Patients initiating cBTKi from 1 January 2020 to 1 January 2023 were identified using claims data, and demographics, therapy line (1L vs 2L+), incident CVAEs, and outcomes were assessed.\"},{\"question\":\"What relationship did the study find between CVAEs and patient outcomes?\",\"answer\":\"Patients experiencing CVAEs had higher switching to next treatment plus death and worse overall survival than those without CVAEs.\"}]","Real-world cardiac events and outcomes in cBTKi-treated chronic lymphocytic leukemia patients | PDF",1790702232]